Phibro Animal Health Corporation (PAHC)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.46B
Last updated: Nov 17, 2026 at 11:04 AM ET
Phibro Animal Health Corporation (PAHC) Financials: Revenue, Profit and Cash Flow
Phibro Animal Health reported revenue of $1.52B for the fiscal year ended Jun 30, 2026, up 17.1% from the year before. That year, net income was $99.72M with a net margin of 6.6%, operating cash flow was $68.95M and free cash flow was $9.87M. The quarter ended Sep 30, 2026 had revenue of $386.77M and net income of $29.52M.
Revenue and Margins
The operating margin was 12.8% in the fiscal year ended Jun 2026. Over the 9 years to Jun 2026, revenue grew from $764.28M, a compound annual rate of 7.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $1.52B | +17.1% | 33.8% | 12.8% | 6.6% |
| Jun 2025 | $1.30B | +27.4% | 30.9% | 8.5% | 3.7% |
| Jun 2024 | $1.02B | +4.1% | 30.8% | 5.2% | 0.2% |
| Jun 2023 | $977.89M | +3.8% | 30.5% | 7.3% | 3.3% |
| Jun 2022 | $942.26M | +13.1% | 30.3% | 8.4% | 5.2% |
| Jun 2021 | $833.35M | +4.1% | 32.6% | 9.0% | 6.5% |
| Jun 2020 | $800.35M | -3.3% | 32.1% | 8.6% | 4.2% |
| Jun 2019 | $828.00M | +1.0% | 32.0% | 10.1% | 6.6% |
| Jun 2018 | $819.98M | +7.3% | 32.5% | 12.1% | 7.9% |
| Jun 2017 | $764.28M | N/A | 32.5% | 12.8% | 8.5% |
Income Statement
In the fiscal year ended Jun 2026, net income rose 106.6% from the year before. In the quarter ended Sep 2026, net income rose 11.3% from the same quarter a year earlier.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.52B | $1.30B | $1.02B | $977.89M | $942.26M | $833.35M | $800.35M | $828.00M | $819.98M | $764.28M |
| Cost of revenue | $1.01B | $896.27M | $704.59M | $679.65M | $656.86M | $561.97M | $543.47M | $563.37M | $553.10M | $516.04M |
| Gross profit | $512.51M | $399.94M | $313.09M | $298.24M | $285.40M | $271.38M | $256.88M | $264.62M | $266.88M | $248.24M |
| Operating income | $194.40M | $110.47M | $53.31M | $71.85M | $78.99M | $74.87M | $69.19M | $83.23M | $98.93M | $97.93M |
| Net income | $99.72M | $48.26M | $2.42M | $32.61M | $49.17M | $54.38M | $33.55M | $54.71M | $64.88M | $64.61M |
| EBITDA | $235.61M | $150.22M | $66.67M | $104.13M | $117.50M | $112.07M | $101.59M | $111.73M | $127.81M | $125.06M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $386.77M | $396.75M | $383.54M | $373.91M | $363.89M | $378.70M | $347.82M | $309.26M | $260.43M | $273.16M | $263.22M | $249.94M |
| Gross profit | $128.54M | $134.40M | $125.67M | $132.66M | $119.78M | $110.01M | $104.57M | $101.87M | $83.50M | $87.15M | $79.60M | $78.62M |
| Operating income | $49.64M | $48.16M | $44.65M | $50.33M | $51.26M | $33.72M | $33.52M | $25.53M | $17.70M | $18.42M | $19.92M | $15.70M |
| Net income | $29.52M | $21.71M | $24.02M | $27.46M | $26.53M | $17.22M | $20.88M | $3.19M | $6.97M | $752.00K | $8.40M | $1.27M |
Balance Sheet
As of Jun 2026, total debt of $732.79M exceeded cash and equivalents by $671.38M.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.50B | $1.36B | $982.18M | $971.40M | $931.70M | $841.33M | $784.10M | $726.67M | $671.68M | $623.40M |
| Current assets | $935.51M | $810.61M | $601.00M | $585.72M | $566.23M | $498.91M | $451.84M | $466.16M | $415.46M | $363.67M |
| Cash and equivalents | $61.42M | $68.04M | $70.61M | $41.28M | $74.25M | $50.21M | $36.34M | $57.57M | $29.17M | $56.08M |
| Total liabilities | $1.12B | $1.08B | $725.54M | $688.89M | $669.26M | $602.80M | $595.90M | $510.66M | $486.73M | $472.24M |
| Short-term debt | $25.02M | $16.25M | $29.80M | $22.30M | $15.00M | $9.38M | $18.75M | $12.54M | $12.58M | $6.25M |
| Long-term debt | $707.77M | $702.43M | $458.29M | $452.54M | $417.93M | $382.71M | $368.26M | $313.63M | $299.80M | $306.89M |
| Shareholder equity | $385.48M | $285.68M | $256.64M | $282.51M | $262.44M | $238.53M | $188.20M | $216.01M | $184.95M | $151.16M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.51B | $1.50B | $1.45B | $1.41B | $1.39B | $1.36B | $1.32B | $1.29B | $966.29M | $982.18M | $979.03M | $972.71M |
| Total liabilities | $1.10B | $1.12B | $1.08B | $1.07B | $1.07B | $1.08B | $1.05B | $1.04B | $707.76M | $725.54M | $708.94M | $701.90M |
| Cash and equivalents | $75.55M | $61.42M | $54.93M | $55.49M | $72.77M | $68.04M | $60.35M | $67.07M | $51.84M | $70.61M | $50.23M | $32.97M |
| Shareholder equity | $417.67M | $385.48M | $361.83M | $332.36M | $311.68M | $285.68M | $265.99M | $246.80M | $258.53M | $256.64M | $270.09M | $270.80M |
Cash Flow
In the fiscal year ended Jun 2026, free cash flow was 14.3% of operating cash flow. Dividends came to 197.2% of it.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $68.95M | $80.12M | $87.59M | $13.31M | $31.65M | $48.31M | $59.35M | $47.17M | $70.01M | $98.39M |
| Capital expenditures | $59.09M | $38.29M | $41.24M | $51.79M | $37.04M | $29.32M | $34.05M | $29.89M | $18.55M | $20.88M |
| Free cash flow | $9.87M | $41.83M | $46.36M | -$38.48M | -$5.39M | $18.99M | $25.30M | $17.28M | $51.46M | $77.50M |
| Dividends paid | $19.46M | $19.45M | $19.44M | $19.44M | $19.44M | $19.43M | $19.42M | $18.59M | $16.07M | $15.83M |
| Investing cash flow | -$71.45M | -$288.69M | -$48.19M | -$74.02M | -$22.58M | -$18.58M | -$120.39M | -$14.13M | -$84.61M | -$21.94M |
| Financing cash flow | -$6.56M | $207.13M | -$6.77M | $26.99M | $16.34M | -$17.00M | $40.94M | -$4.11M | -$11.78M | -$53.74M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $26.08M | $24.09M | $16.21M | $19.35M | $9.30M | $21.27M | $43.15M | $3.08M | $12.62M | $28.43M | $11.41M | $31.56M |
| Capital expenditures | $18.78M | $18.87M | $15.32M | $11.10M | $13.81M | $13.14M | $7.75M | $7.82M | $9.58M | $13.07M | $9.73M | $10.96M |
| Free cash flow | $7.30M | $5.22M | $890.00K | $8.26M | -$4.50M | $8.13M | $35.41M | -$4.75M | $3.04M | $15.36M | $1.68M | $20.60M |
Frequently Asked Questions About PAHC
What is Phibro Animal Health's annual revenue?
Phibro Animal Health reported revenue of $1.52B for the fiscal year ended Jun 30, 2026.
How fast is Phibro Animal Health's revenue growing?
Revenue was up 17.1% for the fiscal year ended Jun 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 15.8%.
Is Phibro Animal Health profitable?
Yes. Phibro Animal Health reported net income of $99.72M for the fiscal year ended Jun 30, 2026, with a net margin of 6.6%.
How much free cash flow does PAHC generate?
For the fiscal year ended Jun 30, 2026, operating cash flow of $68.95M minus capital expenditures of $59.09M produced free cash flow of $9.87M.
How much debt does Phibro Animal Health have?
The balance sheet dated Jun 30, 2026 reported long-term debt of $707.77M, short-term debt of $25.02M and cash and equivalents of $61.42M.
PAHC pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors